Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

Inclusion Criteria: * Any one or more of the following characteristics will qualify patient with T2/T3 prostate cancer for eligibility to current study: * Biopsy proven prostate cancer with Gleason score \> 7 * Pathologic staging TXN1 (on MRI or CT) * Prostate-specific antigen (PSA) \> 10 ng/ml done within a month prior to study entry (the day of first hormonal ablation) and \> 10 days after prostate biopsy. In addition patients must also have: * Performance status \< 2 * Hemoglobin \> 11 grams per deciliter (g/dL), White blood cell (WBC) \> 4000 and platelet count \> 100.000/l * No evidence of other synchronous primary. Prior malignancies does not exclude if the patient is disease free \> 5 years. * Prior or concurrent basal cell or non-invasive squamous carcinoma of the skin is eligible and * Received hormone therapy with any of the following combination for less than 3 months * Lupron / Flutamide * Zoladex/ Flutamide * Lupron/ Casodex * Zoladex/ Casodex Exclusion Criteria: * Clinical stage T1N0, PSA \< 10, and Gleason score less than 7. * Evidence of distant metastasis * Previous surgery for prostate cancer (radical prostatectomy). * Current treatment with ketoconazole, cimetidine or hormone therapy for more than 3 months prior to inclusion in the protocol for prostate cancer * Major medical or psychiatric illness, which in the investigator's opinion may prevent completion of the study and interfere with follow up. * Bilirubin \> 1.5 * Prior chemotherapy is not allowed